EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	2	("3891616").PN.	USPAT; DERWENT	OR	OFF	2006/12/18 12:50
S2	4	(("6855715") or ("6946475")).PN.	USPAT; DERWENT	OR	OFF	2006/12/15 15:26
S3	770	((564/182) or (548/574)).CCLS.	USPAT; DERWENT	OR	OFF	2006/12/18 12:50

18/12/2006,10551734d.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 17:17:42 ON 15 DEC 2006
FILE 'HCAPLUS' ENTERED AT 17:17:42 ON 15 DEC 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.53	73.97

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.53	73.97

FILE 'REGISTRY' ENTERED AT 17:17:54 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 DEC 2006 HIGHEST RN 915690-78-7
DICTIONARY FILE UPDATES: 14 DEC 2006 HIGHEST RN 915690-78-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s electrode
L13 11 ELECTRODE

=> s amino acid deriv?
6522749 AMINO
7992908 ACID
757595 DERIV?
L14 26 AMINO ACID DERIV?
(AMINO(W)ACID(W)DERIV?)

```
=> s l13 and l14
L15           0 L13 AND L14

=> s produc?
L16       13971 PRODUC?

=> s amino acid deriv?
        6522749 AMINO
        7992908 ACID
         757595 DERIV?
L17          26 AMINO ACID DERIV?
                (AMINO(W)ACID(W)DERIV?)

=> s l16 and l17
L18           0 L16 AND L17

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    38.96     112.93

FILE 'HCAPLUS' ENTERED AT 17:19:22 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 Dec 2006  VOL 145 ISS 26
FILE LAST UPDATED: 14 Dec 2006  (20061214/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l14
L19          10 L14

=> d ed abs ibib hitstr 1-10
```

L19 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 29 Sep 2005
AB A Tat-based tolerogen composition comprising at least one immunogenic antigen
couplet to at least one human immunodeficiency virus (HIV) trans-activator
of transcription (Tat) mol. wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Addnl. methods of suppressing organ transplant rejection and methods of treating autoimmune diseases such as rheumatoid arthritis are provided.
ACCESSION NUMBER: 2005:1042276 HCAPLUS
DOCUMENT NUMBER: 143:345319
TITLE: Tolerogen comprising HIV-1 Tat protein or epitope and foreign or endogenous antigen for suppressing organ transplant rejection, inflammation and autoimmune disease
INVENTOR(S): Cohen, David I.
PATENT ASSIGNEE(S): Inist Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090392	A1	20050929	WO 2005-US8634	20050316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2004-553733P	P 20040316
			US 2005-649021P	P 20050131

IT 865508-69-6DP, chimeric derivs.
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; tolerogen comprising HIV-1 Tat protein or epitope and foreign or endogenous antigen for suppressing organ transplant rejection, inflammation and autoimmune disease)
RN 865508-69-6 HCAPLUS
CN Transcription factor tat (synthetic human immunodeficiency virus 1 98-amino acid derivative) (9CI) (CA INDEX NAME)

L19 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Apr 2003
AB Compns. and methods for immunotherapy of malignant diseases, such as leukemia and cancer, are disclosed. The compns. comprise one or more of a
WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1
polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compns. may be used, for example, for the prevention and treatment of
metastatic diseases.
ACCESSION NUMBER: 2003:300439 HCAPLUS
DOCUMENT NUMBER: 138:319680
TITLE: WT1 proteins, polynucleotides and antibodies for cancer diagnosis and therapy
INVENTOR(S): Gaiger, Alexander; McNeill, Patricia D.; Smithgall, Molly; Moulton, Gus; Vedvick, Thomas S.; Sleath, Paul R.; Mossman, Sally; Evans, Lawrence; Spies, A. Gregory; Boydston, Jeremy
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 197 pp., Cont.-in-part of U.S. Ser. No. 785019.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003072767	A1	20030417	US 2001-938864	20010824
US 7063854	B1	20060620	US 1998-164223	19980930
US 7115272	B1	20061003	US 2000-684361	20001006
US 2003082196	A1	20030501	US 2001-785019	20010215
US 7144581	B2	20061205		
ZA 2001002606	A	20020930	ZA 2001-2606	20010329
CA 2425072	AA	20020411	CA 2001-2425072	20011003
WO 2002028414	A1	20020411	WO 2001-US31139	20011003
WO 2002028414	B1	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001096608	A5	20020415	AU 2001-96608	20011003
EP 1328287	A1	20030723	EP 2001-977493	20011003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004510425	T2	20040408	JP 2002-532238	20011003
CN 1505526	A	20040616	CN 2001-819114	20011003
US 2003095971	A1	20030522	US 2001-2603	20011030
US 2003039635	A1	20030227	US 2002-125635	20020416
US 2003198622	A1	20031023	US 2002-195835	20020712
US 2003235557	A1	20031225	US 2002-244830	20020916
US 2003215458	A1	20031120	US 2002-286333	20021030

L19 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 2004018204	A1	20040129	US 2003-427717	20030430
US 2004126362	A1	20040701	US 2003-648780	20030826
AU 2003257511	A1	20031120	AU 2003-257511	20030623
US 2006121046	A1	20060608	US 2006-340431	20060125
PRIORITY APPLN. INFO.:			US 1998-164223	A2 19980930
			US 1999-276484	A2 19990325
			US 2000-684361	A2 20001006
			US 2000-685830	A2 20001009
			US 2001-785019	A2 20010215
			AU 1999-64078	A3 19990930
			US 2001-938864	A 20010824
			WO 2001-US31139	W 20011003
			US 2001-2603	A2 20011030
			US 2002-125635	A2 20020416
			US 2002-195835	A2 20020712
			US 2002-244830	A2 20020916
			US 2002-286333	A2 20021030

IT 514230-24-1P 514230-25-2P 514230-26-3P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; WT1 proteins, polynucleotides and antibodies for cancer diagnosis and therapy)
RN 514230-24-1 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (human 428-amino acid derivative) (9CI) (CA INDEX NAME).

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 514230-25-2 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (human 414-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 514230-26-3 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (human 417-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L19 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Jan 2003
AB Derivs. of haptoglobin that are therapeutically useful as anti-oxidants in
the treatment of oxidative stress are described. Genes encoding these derivs. are also described. Methods of screening haptoglobin derivs for their antioxidant function by their ability to inhibit Hb-dependent oxidation
of a substrate including linolenic acid and LDL. A series of haptoglobin derivs. were prepared as fusion products with glutathione-S-transferase by
standard methods. These were screened for their ability to bind Hb and to
inhibit oxidation of linolenic acid and LDL.
ACCESSION NUMBER: 2003:58257 HCAPLUS
DOCUMENT NUMBER: 138:126930
TITLE: Haptoglobin-derived antioxidants for use in pharmaceuticals for treatment of oxidative stress and the genes encoding them
INVENTOR(S): Levy, Andrew P.
PATENT ASSIGNEE(S): Rappaport Family Institute for Research in the Medical
Sciences, Israel
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006668	A2	20030123	WO 2002-IL530	20020627
WO 2003006668	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003113830	A1	20030619	US 2001-903463	20010711
AU 2002345333	A1	20030129	AU 2002-345333	20020627
PRIORITY APPLN. INFO.:			US 2001-903463 A	20010711
			WO 2002-IL530 W	20020627

IT 488769-09-1 488769-10-4
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; haptoglobin-derived antioxidants for use in pharmaceuticals for treatment of oxidative stress and genes encoding them)

L19 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 488769-09-1 HCAPLUS
CN Haptoglobin (human 129-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 488769-10-4 HCAPLUS
CN Haptoglobin (human 70-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L19 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Apr 2002
AB Compns. and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compns. comprise one or more of a
WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1
polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compns. may be used, for example, for the prevention and treatment of
metastatic diseases.
ACCESSION NUMBER: 2002:275811 HCAPLUS
DOCUMENT NUMBER: 136:308523
TITLE: Compositions and methods for WT1 specific immunotherapy
INVENTOR(S): Gaiger, Alexander; McNeill, Patricia D.; Smithgall, Molly; Moulton, Gus; Vedvick, Thomas S.; Sleath, Paul R.; Mosman, Sally; Evans, Lawrence; Spies, A. Gregory; Boydston, Jeremy
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 260 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028414	A1	20020411	WO 2001-US31139	20011003
WO 2002028414	B1	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 7115272	B1	20061003	US 2000-684361	20001006
US 2003082196	A1	20030501	US 2001-785019	20010215
US 7144581	B2	20061205		
US 2003072767	A1	20030417	US 2001-938864	20010824
CA 2425072	AA	20020411	CA 2001-2425072	20011003
AU 2001096608	A5	20020415	AU 2001-96608	20011003
EP 1328287	A1	20030723	EP 2001-977493	20011003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004510425	T2	20040408	JP 2002-532238	20011003
AU 2003257511	A1	20031120	AU 2003-257511	20031023
PRIORITY APPLN. INFO.:			US 2000-684361 A	20001006
			US 2000-685830 A	20001009
			US 2001-785019 A	20010215
			US 2001-938864 A	20010824

L19 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 1998-164223	A2	19980930
US 1999-276484	A2	19990325
AU 1999-64078	A3	19990930
WO 2001-US31139	W	20011003

IT 410109-27-2P 410109-28-3P 410109-29-4P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; WT1 polypeptides, polynucleotides and antibodies for diagnosis and treatment of leukemias and cancers)
RN 410109-27-2 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (synthetic 428-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 410109-28-3 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (synthetic 414-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 410109-29-4 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (synthetic 417-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 25 Nov 1999
AB An inhibitor of the HCV NS3 protease is disclosed. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the NS4A cofactor. In another embodiment the inhibitor is a bivalent inhibitor comprised of a subsequence, a mutated subsequence or a mutated full-length of a substrate of the NS3 protease linked to a subsequence, a mutated subsequence or a mutated full-length sequence of the HCV NS4A cofactor.
ACCESSION NUMBER: 1999:748338 HCAPLUS
DOCUMENT NUMBER: 132:428
TITLE: Synthetic inhibitors of hepatitis C virus NS3 protease
INVENTOR(S): Zhang, Rumin; Mui, Philip W.; Weber, Patricia C.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S., 27 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5990276	A	19991123	US 1997-853623	19970509
PRIORITY APPLN. INFO.:			US 1996-17470P P	19960510

IT 185352-64-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; synthetic inhibitors of hepatitis C virus NS3 protease)
RN 185352-64-1 HCAPLUS
CN DNA (synthetic hepatitis C virus polyprotein-processing proteinase NS3 255-amino acid deriv. gene) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CA 2303483	AA	19990701	CA 1998-2303483		19981215
AU 9919180	A1	19990712	AU 1999-19180		19981215
AU 765741	B2	20030925			
BR 9813757	A	20001003	BR 1998-13757		19981215
EP 1044217	A2	20001018	EP 1998-963962		19981215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2001526063	T2	20011218	JP 2000-525451		19981215
NZ 503417	A	20021220	NZ 1998-503417		19981215
PRIORITY APPLN. INFO.:			US 1997-68179P	P	19971219
			US 1998-99840P	P	19980911
			WO 1998-US26705	W	19981215

IT 228853-49-4
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(nucleotide sequence; sensitive to apoptosis gene (SAG) and applications for diagnosing and treating neurodegenerative disorders and cancers)
RN 228853-49-4 HCAPLUS
CN DNA (human HeLa cell gene SAG zinc ring finger-containing DNA-binding protein 90-amino acid derivative-specifying plus 3'-flank) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L19 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 09 Jul 1999
AB The invention provides novel genes and polypeptides derived therefrom encoding a redox-sensitive protein that promotes cell growth, protects cells from apoptosis, scavenges oxygen radicals and can be used for the reversion of a tumor phenotype. To identify gene(s) responsible for 1,10-phenanthroline (OP)-induced apoptosis in two murine tumor lines a differential display technique was used and cDNA for an OP-inducible gene SAG was cloned into TA cloning vectors. SAG encodes a novel, redox-sensitive heme-binding protein with a zinc ring finger domain. The SAG protein consists of 113 amino acids with a calculated mol. weight of 12.7 kDa. Sequence homol. searches reveal that SAG is highly conserved among species, suggesting its functional importance. This suggestion is demonstrated by the finding that SAG disruption in yeast is lethal. Two SAG deletion mutants have been detected in human cancer cell lines originating from colon and testis, suggesting its possible role in human carcinogenesis. Overexpression of SAG protein in a human colon carcinoma line, DLD1, and a human neuroblastoma line, SY5Y, protects cells from apoptosis induced by OP, zinc and copper ions. Furthermore, antisense SAG transfection inhibits certain tumor cell phenotypes in DLD1 human cell line and microinjection of SAG RNA stimulates cell growth. We propose that SAG protein is a cellular protective mol. functioning as a redox sensor to buffer oxidative-stress induced damage as well as a growth factor to stimulate cell growth. SAG protein will be an ideal mol. target in the development of drugs against neurodegenerative disorders, cancers, muscle dystrophy, and promoting wound healing.
ACCESSION NUMBER: 1999:425792 HCAPLUS
DOCUMENT NUMBER: 131:69276
TITLE: Sensitive to apoptosis gene (SAG) and its applications for diagnosing and treating neurodegenerative disorders and cancers
INVENTOR(S): Sun, Yi
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932514	A2	19990701	WO 1998-US26705	19981215
WO 9932514	A3	19990910		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9811600	A	19990623	ZA 1998-11600	19980917

L19 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 07 Jul 1999
AB Described is a method for the production of human type I collagen-like proteins by expression of a cassette containing 1-30 (preferably, 5-8) tandemly repeats of the collagen-encoding DNA sequence in Bacillus brevis, followed by recovering the collagen products secreted into the medium by the B. brevis. Preparation of neutral or hydrophilic artificial collagen (gelatin) from the culture of transgenic B. brevis was demonstrated.
ACCESSION NUMBER: 1999:417709 HCAPLUS
DOCUMENT NUMBER: 131:98461
TITLE: Recombinant preparation of human collagen-like proteins with Bacillus brevis
INVENTOR(S): Kashino, Tsutomu; Takahashi, Haruo; Yamada, Yukio; Hirai, Masana; Takagi, Hiroaki; Ebisu, Shogo; Watanabe, Fumiko
PATENT ASSIGNEE(S): Toyota Central Research and Development Laboratories, Inc., Japan; Higeta Shoyu Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11178574	A2	19990706	JP 1997-353216	19971222
PRIORITY APPLN. INFO.:			JP 1997-353216	19971222

IT 230624-07-4P 230624-08-5P
RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; recombinant preparation of collagen-like proteins with Bacillus brevis)
RN 230624-07-4 HCAPLUS
CN Collagen (human type I 231-amino-acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 230624-08-5 HCAPLUS
CN Collagen (human type I 168-amino-acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 230624-09-6P 230624-10-9P
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(nucleotide sequence; recombinant preparation of collagen-like proteins with Bacillus brevis)
RN 230624-09-6 HCAPLUS
CN DNA (synthetic human type I collagen 231-amino-acid derivative-specifying) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 230624-10-9 HCAPLUS
CN DNA (synthetic human type I collagen 168-amino-acid derivative-specifying)

L19 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L19 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Mar 1998
AB We described genetically engineered syntheses of tandem repetitive polypeptides consisting of glycine-rich sequence, GlyLeuGlyGlyGlnGlyGlyGlyAlaGlyGlnGlyGlyTyrGly, designated SCAP(1), in spidroin I of spider dragline silk from Nephila clavipes and the secondary conformational analyses in the solid state by Fourier transform IR measurements. The polypeptides composed of 4, 5, 6, 7, 11, 12, or 13 repeats of SCAP(1) were expressed in Escherichia coli, purified by nickel chelate affinity chromatog., and then cleaved with cyanogen bromide to release N- and C-terminal extensions. Typical yields were from 1.2 to 5.2 mg of lyophilized uncleaved polypeptides per L of fermentation medium at an absorbance of 2.0 at 600 nm, and the production levels increased with decreasing the mol. weight of the expressed polypeptides. The lyophilized powder of cleaved SCAP(13) adopted the random coil, whereas the cast film from formic acid formed the β-sheet structure. The conformational results might indicate that the glycine-rich sequence formed β-sheet structure in spidroin I. Cleaved SCAP(13) started to decompose under nitrogen at ca. 230°C, which was in agreement with the decomposition temperature of the spider dragline silk from N. clavipes.
ACCESSION NUMBER: 1998:129222 HCAPLUS
DOCUMENT NUMBER: 128:266743
TITLE: Genetically engineered syntheses of tandem repetitive polypeptides consisting of glycine-rich sequence of spider dragline silk
AUTHOR(S): Fukushima, Yasumasa
CORPORATE SOURCE: Research and Development Center, Unitika Ltd., Kyoto, 611, Japan
SOURCE: Biopolymers (1998), 45(4), 269-279
CODEN: BIPMAA; ISSN: 0006-3525
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 200445-99-4P
RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(genetically engineered syntheses of tandem repetitive polypeptides consisting of glycine-rich sequence of spider dragline silk)
RN 200445-99-4 HCAPLUS
CN Protein (synthetic spider dragline silk 105-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Nov 1997
AB Polypeptides with a repeating sequence of glycine-rich sequence of spider dragline silk were synthesized in E. Coli. The polypeptide in the solid state formed a β-sheet structure which exists in crystalline region of spider silk.
ACCESSION NUMBER: 1997:739097 HCAPLUS
DOCUMENT NUMBER: 128:72114
TITLE: Secondary structural studies of biosynthetic polypeptides with a repeating sequence of glycine-rich sequence of spider dragline silk
AUTHOR(S): Fukushima, Yasumasa; Nakajima, Hiroshi
CORPORATE SOURCE: Research and Development Center, Unitika Ltd., Kyoto, 611, Japan
SOURCE: Chemistry Letters (1997), (11), 1087-1088
CODEN: CMLTAG; ISSN: 0366-7022
PUBLISHER: Chemical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 200445-99-4P 200446-00-0P 200446-01-1P
200446-02-2P 200446-03-3P 200446-04-4P
200446-05-5P
RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; secondary structure of biosynthetic polypeptides with a repeating sequence of glycine-rich sequence similar to spider dragline silk protein spidroin)
RN 200445-99-4 HCAPLUS
CN Protein (synthetic spider dragline silk 105-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-00-0 HCAPLUS
CN Protein (synthetic spider dragline silk 120-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-01-1 HCAPLUS
CN Protein (synthetic spider dragline silk 135-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-02-2 HCAPLUS
CN Protein (synthetic spider dragline silk 150-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-03-3 HCAPLUS
CN Protein (synthetic spider dragline silk 210-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-04-4 HCAPLUS
CN Protein (synthetic spider dragline silk 225-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-05-5 HCAPLUS
CN Protein (synthetic spider dragline silk 240-amino acid derivative) (9CI)

L19 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 27 Jan 1997
AB Soluble HCV NS3 protease, including the NS3 protease fused to a solubilizing
motif; a fusion of the NS3 and NS4 regions under conditions where they are
not cleaved by the NS3 protease; bacterially expressed soluble HCV NS3 protease; and host cells wherein at least 1% of the cell's total protein is soluble hepatitis C virus (HCV) NS3 protease are claimed. Expts. demonstrated that E. coli-expressed NS3 protease variants catalyzed cleavage of HCV polyproteins and synthetic peptide substrates. The processing activity of NS3 was enhanced by NS4A and its derivs. The activity of the fusion protein containing the NS3 catalytic domain and NS4A
was much superior to that of the NS3 catalytic domain alone. A surface plasmon resonance assay for NS3 protease was developed and described.
ACCESSION NUMBER: 1997:56164 HCAPLUS
DOCUMENT NUMBER: 126:71201
TITLE: Recombinant, soluble, active hepatitis C virus NS3 protease
INVENTOR(S): Dasmahapatra, Bimalendu; Murray, Michael G.; Ramanathan, Lata; Butkiewicz, Nancy J.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9636702	A2	19961121	WO 1996-US6387	19960509
WO 9636702	A3	19970116		
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5843752	A	19981201	US 1995-440409	19950512
CA 2220575	AA	19961121	CA 1996-2220575	19960509
CA 2220575	C	20011225		
AU 9657291	A1	19961129	AU 1996-57291	19960509
EP 826038	A2	19980304	EP 1996-915539	19960509
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI				
JP 10507933	T2	19980804	JP 1996-534876	19960509
JP 3091231	B2	20000925		
PRIORITY APPLN. INFO.:			US 1995-440409 A	19950512
			WO 1996-US6387 W	19960509

IT 185352-54-9
RL: PRP (Properties)

L19 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(amino acid sequence; recombinant, sol., active hepatitis C virus NS3 protease)
RN 185352-54-9 HCAPLUS
CN Proteinase, polyprotein-processing, NS3 (synthetic hepatitis C virus 270-amino acid deriv.) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 185352-61-8 185352-62-9 185352-63-0
185352-64-1
RL: PRP (Properties)
(nucleotide sequence; recombinant, soluble, active hepatitis C virus NS3 protease)
RN 185352-61-8 HCAPLUS
CN DNA (synthetic hepatitis C virus polyprotein-processing proteinase NS3 270-amino acid deriv. gene) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 185352-62-9 HCAPLUS
CN DNA (synthetic hepatitis C virus polyprotein-processing proteinase NS3 237-amino acid deriv. gene) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 185352-63-0 HCAPLUS
CN DNA (synthetic hepatitis C virus polyprotein-processing proteinase NS3 250-amino acid deriv. gene) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 185352-64-1 HCAPLUS
CN DNA (synthetic hepatitis C virus polyprotein-processing proteinase NS3 255-amino acid deriv. gene) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     38.29     151.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -7.50      -7.50

FILE 'REGISTRY' ENTERED AT 17:21:08 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 DEC 2006  HIGHEST RN 915690-78-7
DICTIONARY FILE UPDATES:  14 DEC 2006  HIGHEST RN 915690-78-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s amino acid derivatives
      6522749 AMINO
      7992908 ACID
          170 DERIVATIVES
L20         0 AMINO ACID DERIVATIVES
                (AMINO(W)ACID(W)DERIVATIVES)

=> s amino acid derivative
      6522749 AMINO
      7992908 ACID
         3225 DERIVATIVE
L21        21 AMINO ACID DERIVATIVE
                (AMINO(W)ACID(W)DERIVATIVE)

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     29.00     180.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                      0.00      -7.50
```

18/12/2006,10551734d.trn

FILE 'HCAPLUS' ENTERED AT 17:21:48 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 14 Dec 2006 (20061214/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l21
L22 8 L21

=> d ed abs ibib hitstr 1-8

L22 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 29 Sep 2005
AB A Tat-based tolerogen composition comprising at least one immunogenic antigen
couplet to at least one human immunodeficiency virus (HIV) trans-activator
of transcription (Tat) mol. wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Addnl. methods of suppressing organ transplant rejection and methods of treating autoimmune diseases such as rheumatoid arthritis are provided.
ACCESSION NUMBER: 2005:1042276 HCAPLUS
DOCUMENT NUMBER: 143:345319
TITLE: Tolerogen comprising HIV-1 Tat protein or epitope and foreign or endogenous antigen for suppressing organ transplant rejection, inflammation and autoimmune disease
INVENTOR(S): Cohen, David I.
PATENT ASSIGNEE(S): Inist Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090392	A1	20050929	WO 2005-US8634	20050316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2004-553733P	P 20040316
			US 2005-649021P	P 20050131

IT 865508-69-6DP, chimeric deriva.
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; tolerogen comprising HIV-1 Tat protein or epitope and foreign or endogenous antigen for suppressing organ transplant rejection, inflammation and autoimmune disease)
RN 865508-69-6 HCAPLUS
CN Transcription factor tat (synthetic human immunodeficiency virus 1 98-amino acid derivative) (9CI) (CA INDEX NAME)

L22 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Apr 2003
AB Compns. and methods for immunotherapy of malignant diseases, such as leukemia and cancer, are disclosed. The compns. comprise one or more of a
WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1
polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compns. may be used, for example, for the prevention and treatment of
metastatic diseases.
ACCESSION NUMBER: 2003:300439 HCAPLUS
DOCUMENT NUMBER: 138:319680
TITLE: WT1 proteins, polynucleotides and antibodies for cancer diagnosis and therapy
INVENTOR(S): Gaiger, Alexander; McNeill, Patricia D.; Smithgall, Molly; Moulton, Gus; Vedvick, Thomas S.; Sleath, Paul R.; Mossman, Sally; Evans, Lawrence; Spies, A. Gregory; Boydston, Jeremy
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 197 pp., Cont.-in-part of U.S. Ser. No. 785019.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003072767	A1	20030417	US 2001-938864	20010824
US 7063854	B1	20060620	US 1998-164223	19980930
US 7115272	B1	20061003	US 2000-684361	20001006
US 2003082196	A1	20030501	US 2001-785019	20010215
US 7144581	B2	20061205		
ZA 2001002606	A	20020930	ZA 2001-2606	20010329
CA 2425072	AA	20020411	CA 2001-2425072	20011003
WO 2002028414	A1	20020411	WO 2001-US31139	20011003
WO 2002028414	B1	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001096608	A5	20020415	AU 2001-96608	20011003
EP 1328287	A1	20030723	EP 2001-977493	20011003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004510425	T2	20040408	JP 2002-532238	20011003
CN 1505526	A	20040616	CN 2001-819114	20011003
US 2003095971	A1	20030522	US 2001-2603	20011030
US 2003039635	A1	20030227	US 2002-125635	20020416
US 2003198622	A1	20031023	US 2002-195835	20020712
US 2003235557	A1	20031225	US 2002-244830	20020916
US 2003215458	A1	20031120	US 2002-286333	20021030

L22 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 2004018204	A1	20040129	US 2003-427717	20030430
US 2004126362	A1	20040701	US 2003-648780	20030826
AU 2003257511	A1	20031120	AU 2003-257511	20031023
US 2006121046	A1	20060608	US 2006-340431	20060125
PRIORITY APPLN. INFO.:			US 1998-164223	A2 19980930
			US 1999-276484	A2 19990325
			US 2000-684361	A2 20001006
			US 2000-685830	A2 20001009
			US 2001-785019	A2 20010215
			AU 1999-64078	A3 19990930
			US 2001-938864	A 20010824
			WO 2001-US31139	W 20011003
			US 2001-2603	A2 20011030
			US 2002-125635	A2 20020416
			US 2002-195835	A2 20020712
			US 2002-244830	A2 20020916
			US 2002-286333	A2 20021030

IT 514230-24-1P 514230-25-2P 514230-26-3P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; WT1 proteins, polynucleotides and antibodies for cancer diagnosis and therapy)
RN 514230-24-1 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (human 428-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 514230-25-2 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (human 414-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 514230-26-3 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (human 417-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L22 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Jan 2003
AB Derivs. of haptoglobin that are therapeutically useful as anti-oxidants in
the treatment of oxidative stress are described. Genes encoding these derivs. are also described. Methods of screening haptoglobin derivs for their antioxidant function by their ability to inhibit Hb-dependent oxidation
of a substrate including linolenic acid and LDL. A series of haptoglobin derivs. were prepared as fusion products with glutathione-S-transferase by
standard methods. These were screened for their ability to bind Hb and to
inhibit oxidation of linolenic acid and LDL.
ACCESSION NUMBER: 2003:58257 HCAPLUS
DOCUMENT NUMBER: 138:126930
TITLE: Haptoglobin-derived antioxidants for use in pharmaceuticals for treatment of oxidative stress and the genes encoding them
INVENTOR(S): Levy, Andrew P.
PATENT ASSIGNEE(S): Rappaport Family Institute for Research in the Medical
Sciences, Israel
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006668	A2	20030123	WO 2002-IL530	20020627
WO 2003006668	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003113830	A1	20030619	US 2001-903463	20010711
AU 2002345333	A1	20030129	AU 2002-345333	20020627
PRIORITY APPLN. INFO.:			US 2001-903463 A	20010711
			WO 2002-IL530 W	20020627

IT 488769-09-1 488769-10-4
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; haptoglobin-derived antioxidants for use in pharmaceuticals for treatment of oxidative stress and genes encoding them)

L22 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 488769-09-1 HCAPLUS
CN Haptoglobin (human 129-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 488769-10-4 HCAPLUS
CN Haptoglobin (human 70-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L22 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Apr 2002
AB Compns. and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compns. comprise one or more of a
WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1
polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compns. may be used, for example, for the prevention and treatment of
metastatic diseases.
ACCESSION NUMBER: 2002:275811 HCAPLUS
DOCUMENT NUMBER: 136:308523
TITLE: Compositions and methods for WT1 specific immunotherapy
INVENTOR(S): Gaiger, Alexander; McNeill, Patricia D.; Smithgall, Molly; Moulton, Gus; Vedvick, Thomas S.; Sleath, Paul R.; Mosseman, Sally; Evans, Lawrence; Spies, A. Gregory; Boydston, Jeremy
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 260 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028414	A1	20020411	WO 2001-US31139	20011003
WO 2002028414	B1	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 7115272	B1	20061003	US 2000-684361	20001006
US 2003082196	A1	20030501	US 2001-785019	20010215
US 7144581	B2	20061205		
US 2003072767	A1	20030417	US 2001-938864	20010824
CA 2425072	AA	20020411	CA 2001-2425072	20011003
AU 2001096608	A5	20020415	AU 2001-96608	20011003
EP 1328287	A1	20030723	EP 2001-977493	20011003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004510425	T2	20040408	JP 2002-532238	20011003
AU 2003257511	A1	20031120	AU 2003-257511	20031023
PRIORITY APPLN. INFO.:			US 2000-684361 A	20001006
			US 2000-685830 A	20001009
			US 2001-785019 A	20010215
			US 2001-938864 A	20010824

L22 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 1998-164223	A2	19980930
US 1999-276484	A2	19990325
AU 1999-64078	A3	19990930
WO 2001-US31139	W	20011003

IT 410109-27-2P 410109-28-3P 410109-29-4P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; WT1 polypeptides, polynucleotides and antibodies for diagnosis and treatment of leukemias and cancers)
RN 410109-27-2 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (synthetic 428-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 410109-28-3 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (synthetic 414-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 410109-29-4 HCAPLUS
CN Transcription factor WT1 (Wilms' tumor suppressor 1) (synthetic 417-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L22 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 09 Jul 1999
AB The invention provides novel genes and polypeptides derived therefrom encoding a redox-sensitive protein that promotes cell growth, protects cells from apoptosis, scavenges oxygen radicals and can be used for the reversion of a tumor phenotype. To identify gene(s) responsible for 1,10-phenanthroline (OP)-induced apoptosis in two murine tumor lines a differential display technique was used and cDNA for an OP-inducible gene SAG was cloned into TA cloning vectors. SAG encodes a novel, redox-sensitive heme-binding protein with a zinc ring finger domain. The SAG protein consists of 113 amino acids with a calculated mol. weight of 12.7 kDa. Sequence homol. searches reveal that SAG is highly conserved among species, suggesting its functional importance. This suggestion is demonstrated by the finding that SAG disruption in yeast is lethal. Two SAG deletion mutants have been detected in human cancer cell lines originating from colon and testis, suggesting its possible role in human carcinogenesis. Overexpression of SAG protein in a human colon carcinoma line, DLD1, and a human neuroblastoma line, SY5Y, protects cells from apoptosis induced by OP, zinc and copper ions. Furthermore, antisense SAG transfection inhibits certain tumor cell phenotypes in DLD1 human cell line and microinjection of SAG RNA stimulates cell growth. We propose that SAG protein is a cellular protective mol. functioning as a redox sensor to buffer oxidative-stress induced damage as well as a growth factor to stimulate cell growth. SAG protein will be an ideal mol. target in the development of drugs against neurodegenerative disorders, cancers, muscle dystrophy, and promoting wound healing.
ACCESSION NUMBER: 1999:425792 HCAPLUS
DOCUMENT NUMBER: 131:69276
TITLE: Sensitive to apoptosis gene (SAG) and its applications for diagnosing and treating neurodegenerative disorders and cancers
INVENTOR(S): Sun, Yi
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932514	A2	19990701	WO 1998-US26705	19981215
WO 9932514	A3	19990910		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9811600	A	19990623	ZA 1998-11600	19980917

L22 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CA 2303483	AA	19990701	CA 1998-2303483	19981215
AU 9919180	A1	19990712	AU 1999-19180	19981215
AU 765741	B2	20030925		
BR 9813757	A	20001003	BR 1998-13757	19981215
EP 1044217	A2	20001018	EP 1998-963962	19981215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526063	T2	20011218	JP 2000-525451	19981215
NZ 503417	A	20021220	NZ 1998-503417	19981215
PRIORITY APPLN. INFO.:			US 1997-68179P	P 19971219
			US 1998-99840P	P 19980911
			WO 1998-US26705	W 19981215

IT 228853-49-4
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(nucleotide sequence; sensitive to apoptosis gene (SAG) and applications for diagnosing and treating neurodegenerative disorders and cancers)
RN 228853-49-4 HCAPLUS
CN DNA (human HeLa cell gene SAG zinc ring finger-containing DNA-binding protein 90-amino acid derivative-specifying plus 3'-flank) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L22 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 07 Jul 1999
AB Described is a method for the production of human type I collagen-like proteins by expression of a cassette containing 1-30 (preferably, 5-8) tandemly repeats of the collagen-encoding DNA sequence in Bacillus brevis, followed by recovering the collagen products secreted into the medium by the B. brevis. Preparation of neutral or hydrophilic artificial collagen (gelatin) from the culture of transgenic B. brevis was demonstrated.
ACCESSION NUMBER: 1999:417709 HCAPLUS
DOCUMENT NUMBER: 131:98461
TITLE: Recombinant preparation of human collagen-like proteins with Bacillus brevis
INVENTOR(S): Kashino, Tsutomu; Takahashi, Haruo; Yamada, Yukio; Hirai, Masana; Takagi, Hiroaki; Ebisu, Shogo; Watanabe, Fumiko
PATENT ASSIGNEE(S): Toyota Central Research and Development Laboratories, Inc., Japan; Higeta Shoyu Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11178574	A2	19990706	JP 1997-353216	19971222
PRIORITY APPLN. INFO.:			JP 1997-353216	19971222

IT 230624-07-4P 230624-08-5P
RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; recombinant preparation of collagen-like proteins with Bacillus brevis)
RN 230624-07-4 HCAPLUS
CN Collagen (human type I 231-amino-acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 230624-08-5 HCAPLUS
CN Collagen (human type I 168-amino-acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 230624-09-6P 230624-10-9P
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(nucleotide sequence; recombinant preparation of collagen-like proteins with Bacillus brevis)
RN 230624-09-6 HCAPLUS
CN DNA (synthetic human type I collagen 231-amino-acid derivative-specifying) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 230624-10-9 HCAPLUS
CN DNA (synthetic human type I collagen 168-amino-acid derivative-specifying)

L22 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L22 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Mar 1998
AB We described genetically engineered syntheses of tandem repetitive polypeptides consisting of glycine-rich sequence, GlyLeuGlyGlyGlnGlyGlyGlyAlaGlyGlnGlyGlyTyrGly, designated SCAP(1), in spidroin I of spider dragline silk from Nephila clavipes and the secondary conformational analyses in the solid state by Fourier transform IR measurements. The polypeptides composed of 4, 5, 6, 7, 11, 12, or 13 repeats of SCAP(1) were expressed in Escherichia coli, purified by nickel chelate affinity chromatog., and then cleaved with cyanogen bromide to release N- and C-terminal extensions. Typical yields were from 1.2 to 5.2 mg of lyophilized uncleaved polypeptides per L of fermentation medium at an absorbance of 2.0 at 600 nm, and the production levels increased with decreasing the mol. weight of the expressed polypeptides. The lyophilized powder of cleaved SCAP(13) adopted the random coil, whereas the cast film from formic acid formed the β-sheet structure. The conformational results might indicate that the glycine-rich sequence formed β-sheet structure in spidroin I. Cleaved SCAP(13) started to decompose under nitrogen at ca. 230°C, which was in agreement with the decomposition temperature of the spider dragline silk from N. clavipes.
ACCESSION NUMBER: 1998:129222 HCAPLUS
DOCUMENT NUMBER: 128:266743
TITLE: Genetically engineered syntheses of tandem repetitive polypeptides consisting of glycine-rich sequence of spider dragline silk
AUTHOR(S): Fukushima, Yasumasa
CORPORATE SOURCE: Research and Development Center, Unitika Ltd., Kyoto, 611, Japan
SOURCE: Biopolymers (1998), 45(4), 269-279
CODEN: BIPMAA; ISSN: 0006-3525
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 200445-99-4P
RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(genetically engineered syntheses of tandem repetitive polypeptides consisting of glycine-rich sequence of spider dragline silk)
RN 200445-99-4 HCAPLUS
CN Protein (synthetic spider dragline silk 105-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-05-5 HCAPLUS
CN Protein (synthetic spider dragline silk 240-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Nov 1997
AB Polypeptides with a repeating sequence of glycine-rich sequence of spider dragline silk were synthesized in E. Coli. The polypeptide in the solid state formed a β-sheet structure which exists in crystalline region of spider silk.
ACCESSION NUMBER: 1997:739097 HCAPLUS
DOCUMENT NUMBER: 128:72114
TITLE: Secondary structural studies of biosynthetic polypeptides with a repeating sequence of glycine-rich sequence of spider dragline silk
AUTHOR(S): Fukushima, Yasumasa; Nakajima, Hiroshi
CORPORATE SOURCE: Research and Development Center, Unitika Ltd., Kyoto, 611, Japan
SOURCE: Chemistry Letters (1997), (11), 1087-1088
CODEN: CMLTAG; ISSN: 0366-7022
PUBLISHER: Chemical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 200445-99-4P 200446-00-0P 200446-01-1P 200446-02-2P 200446-03-3P 200446-04-4P 200446-05-5P
RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; secondary structure of biosynthetic polypeptides with a repeating sequence of glycine-rich sequence similar to spider dragline silk protein spidroin)
RN 200445-99-4 HCAPLUS
CN Protein (synthetic spider dragline silk 105-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-00-0 HCAPLUS
CN Protein (synthetic spider dragline silk 120-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-01-1 HCAPLUS
CN Protein (synthetic spider dragline silk 135-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-02-2 HCAPLUS
CN Protein (synthetic spider dragline silk 150-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-03-3 HCAPLUS
CN Protein (synthetic spider dragline silk 210-amino acid derivative) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 200446-04-4 HCAPLUS
CN Protein (synthetic spider dragline silk 225-amino acid derivative) (9CI) (CA INDEX NAME)

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    27.09     207.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -6.00     -13.50

FILE 'REGISTRY' ENTERED AT 17:22:29 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 DEC 2006  HIGHEST RN 915690-78-7
DICTIONARY FILE UPDATES:  14 DEC 2006  HIGHEST RN 915690-78-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s electrode
L23          11 ELECTRODE

=> d scan
```

```
L23  11 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN   Indium tin oxide (9CI)
MF   In . O . Sn
CI   TIS

  Component    |       Ratio
***************+*********************
O              |         x
In             |         x
Sn             |         x

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0
```

```
=> d ed abs ibib hitstr 1-11
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual
fields or predefined formats.  The predefined substance formats
are:  (RN = CAS Registry Number)

REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD    - Protein sequence data, includes RN
SQD3   - Same as SQD, but 3-letter amino acid codes are used
SQN    - Protein sequence name information, includes RN

CALC   - Table of calculated properties
EPROP  - Table of experimental properties
PROP   - EPROP and CALC

Any CA File format may be combined with any substance format to
obtain CA references citing the substance.  The substance formats
must be cited first.  The CA File predefined formats are:

ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when
it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented,
with text labels.

For additional information, please consult the following help
messages:

HELP DFIELDS -- To see a complete list of individual display fields.
```

HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> d ed abs ibib

L23 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Jan 1994
AB The high alloy overlays of ECoCrA and ENiCrMo-4 were diluted by iron from the mild steel substrate to different extents, depending on the welding process and parameters. The dilution of major alloy constituents can be >30% in manual metal-arc welding. The dilution in plasma transfered-arc welding using powder alloys can be controlled within 5-10%. The effect of dilution in the overlays using both processes on the microstructure, hardness, wear, and corrosion properties were studied.
ACCESSION NUMBER: 120:59512 CA
TITLE: Study of dilution of high alloy overlays
AUTHOR(S): Chattopadhyay, R.; Kammer, P. A.
CORPORATE SOURCE: Ewac Alloys Ltd., Bombay, India
SOURCE: Int. Trends Weld. Sci. Technol., Proc. Int. Conf. Trends Weld. Res., 3rd (1993), Meeting Date 1992, 455-60. Editor(s): David, Stan A.; Vitek, J. M. ASM: Materials Park, Ohio.
CODEN: 59GAAM
DOCUMENT TYPE: Conference
LANGUAGE: English